5h agoCNBCNEUTRAL 50General
Stocks making the biggest moves midday: Carnival, Fair Isaac, Bloom Energy, Iovance Biotherapeutics & more
Here are some of the companies making headlines in midday trading.
Archived explainer. For the current picture see today's IOVA page.
Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Up Today?
By the Top Tier Newswire AI Desk · September 29, 2026 at 1:03 PM ET · reviewed against 18 wire stories
IOVANCE BIOTHERAPEUT (IOVA) is up +37.72% in the latest session. Our newswire has captured 18 stories on IOVA across 12 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
IOVA stock surged 37.72% to $15.14 in a single session driven by a raised revenue outlook and strong demand for its cancer therapies. The company lifted its 2026 revenue guidance by $55 million at the midpoint to $410, $420 million, citing robust U.S. demand for Amtagvi and Proleukin. Analysts and traders responded with bullish sentiment, reflected in a sharp price rise and unusual options activity.
What Happened
Iovance Biotherapeutics announced a significant upward revision of its full-year 2026 revenue guidance, citing sustained strong demand for its melanoma treatments. The company raised its revenue forecast to a range of $410, $420 million, up from $350, $370 million previously. This update came as H.C. Wainwright raised its price target for the stock to $20 from $9, while TD Cowen also increased its price target based on the improved revenue outlook. The stock opened with a slight $0.5% gap up and climbed steadily throughout the session, reaching a high of $15.16 at 1:00 PM ET. The move was supported by strong retail and institutional interest, with call volume on The Fly above normal and a notable $94K call premium recorded in the options market.
What The Data Shows
The stock’s intraday performance was dramatic, with a 3.0x surge in volume to 46.5 million shares. It closed the session near its high of $15.11, a level that marked a new 28th 52-week high for the day. The stock had traded in a relatively narrow range of $10.67 to $10.81 over the previous eight sessions before this breakout. Despite being unprofitable with a net margin of -89.1% and a negative EPS of -0.71, the company’s revenue grew by 34.5% in the trailing twelve months. Short interest stood at 21%, suggesting potential for further upward pressure if the trend continues.
What To Watch
The company’s updated revenue guidance and analyst upgrades indicate continued confidence in its growth trajectory. Investors should monitor the stock’s performance ahead of any upcoming catalysts or earnings reports.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IOVA by the numbers
Last: $15.14Session: +37.72%7 sessions: +46.63%Coverage: 18 stories / 12 sourcesAI sentiment: 67/100 (bullish)Mkt cap: $5.0B52w: $1.76 to $11.16
The headlines behind the move
5h agoBarron'sBULLISH 73Product/PR
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
6h agoThe FlyBULLISH 68General
Iovance Biotherapeutics rises 27.8%
6h agoMarketChameleonBULLISH 73Earnings
Iovance lifts 2026 revenue outlook by $55 million at the midpoint as Amtagvi and Proleukin demand stays strong September 29, 2026
Iovance Biotherapeutics raised full-year 2026 revenue guidance to $410–$420 million, a $55 million midpoint increase from its prior $350–$370 million range, citing strong U.S. demand for Amtagvi and Proleukin. The company also highlighted record Q2 2026 product revenue of $99.3 million and an ATC network approaching 100 centers, with at least 110 targeted by year-end 2026.
7h agoInvesting.com Analyst RatingsBULLISH 61Analyst
TD Cowen raises Iovance Biotherapeutics price target on revenue outlook
TD Cowen raises Iovance Biotherapeutics price target on revenue outlook
7h agoThe FlyBULLISH 62General
Iovance Biotherapeutics call volume above normal and directionally bullish
7h agoThe FlyBULLISH 67Analyst
Iovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright
7h agoStocktwits NewsBULLISH 67Earnings
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IOVA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IOVA move explainers: 2026-09-29 · 2026-08-24 · 2026-08-21 · 2026-08-20 · 2026-08-19 · 2026-08-06